3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase NA
1
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
9
Small Cell Lung Carcinoma
7
Biliary Tract Neoplasms
7
Carcinoma, Hepatocellular
6
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Carcinoma
4
Neoplasm Metastasis
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma Extensive Disease
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Non-Muscle Invasive Bladder Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Urothelial Cancer
1
Sarcoma
1
Radiation Pneumonitis
1
Pancoast Syndrome
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non Small Cell Lung Carcinoma NSCLC
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Cisplatin
21
Radiotherapy
16
Fluorouracil
16
Paclitaxel
15
Irinotecan
8
Docetaxel
8
Neoadjuvant Therapy
6
Drug Therapy
5
tislelizumab
4
sintilimab
4
Surgical Procedures, Operative
4
Radiation
4
Oxaliplatin
4
Leucovorin
4
Esophagectomy
4
Capecitabine
4
toripalimab
3
pembrolizumab
3
TP protocol
3
Chemotherapy, Adjuvant
3
S 1 (combination)
2
Levoleucovorin
2
Injections
2
Cetuximab
2
Carboplatin
2
lenvatinib
1
irinotecan sucrosofate
1
durvalumab
1
atropine sulfate-diphenoxylate hydrochloride drug combination
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Esophageal Squamous Cell Carcinoma
×
durvalumab
×
Clear all
NCT04550260
2026-05-13
KUNLUN
AstraZeneca
Phase 3
Active not recruiting
640 enrolled